Literature DB >> 8476719

Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis.

M Hattori1, K Ito, H Kawaguchi, T Tanaka, R Kubota, M Khono.   

Abstract

Results of recent animal studies have lent support to the hypothesis that hyperlipidaemia may contribute to renal injury. This report documents the case of a 15-year-old boy with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis (FGS) who showed an improvement in renal function and proteinuria as a result of treatment with low-density lipoprotein aphaeresis (LDL-A) combined with pravastatin. Although further work is required to determine the efficacy of lipid-lowering therapy in progressive glomerular disease in humans, the combination of LDL-A and pravastatin is likely be included in the choice of treatment modalities available for patients with drug-resistant nephrotic syndrome due to FGS.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8476719     DOI： 10.1007/bf00864397

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  12 in total

1.  Partial remission of nephrotic syndrome in patient on long-term simvastatin.

Authors:  A J Rabelink; R J Hené; D W Erkelens; J A Joles; H A Koomans
Journal:  Lancet       Date:  1990-04-28       Impact factor: 79.321

Review 2.  Low-density lipoprotein: an old substance with a new function?

Authors:  L H Block; A Pletscher
Journal:  Trends Pharmacol Sci       Date:  1988-06       Impact factor: 14.819

3.  A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis).

Authors:  H Mabuchi; I Michishita; M Takeda; H Fujita; J Koizumi; R Takeda; S Takada; M Oonishi
Journal:  Atherosclerosis       Date:  1987-11       Impact factor: 5.162

Review 4.  Less commonly recognized features of childhood nephrotic syndrome.

Authors:  J Strauss; G Zilleruelo; M Freundlich; C Abitol
Journal:  Pediatr Clin North Am       Date:  1987-06       Impact factor: 3.278

5.  Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).

Authors:  K Tojo; S Sakai; T Miyahara
Journal:  Nihon Jinzo Gakkai Shi       Date:  1988-09

6.  Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits.

Authors:  S Yokoyama; R Hayashi; T Kikkawa; N Tani; S Takada; K Hatanaka; A Yamamoto
Journal:  Arteriosclerosis       Date:  1984 May-Jun

7.  Evidence for a renal origin of urinary thromboxane B2 in health and disease.

Authors:  C Patrono; G Ciabattoni; P Patrignani; P Filabozzi; E Pinca; M A Satta; D van Dorne; G A Cinotti; F Pugliese; A Pierucci; B M Simonetti
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1983

Review 8.  Hyperlipidemia and progressive renal disease.

Authors:  W F Keane; W S Mulcahy; B L Kasiske; Y Kim; M P O'Donnell
Journal:  Kidney Int Suppl       Date:  1991-04       Impact factor: 10.545

9.  Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation.

Authors:  J R Diamond; M J Karnovsky
Journal:  Kidney Int       Date:  1987-11       Impact factor: 10.612

10.  Preliminary report: renal thromboxane A2 synthesis in children with frequent relapsing nephrotic syndrome.

Authors:  A Benigni; G Rizzoni; A Antolini; A Piccinelli; G Remuzzi
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321
View more
  8 in total

Review 1.  An update on LDL apheresis for nephrotic syndrome.

Authors:  Rupesh Raina; Vinod Krishnappa
Journal:  Pediatr Nephrol       Date:  2018-09-14       Impact factor: 3.714

2.  Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis.

Authors:  Yukihiko Kawasaki; Sigeo Suzuki; Ayumi Matsumoto; Kei Takano; Kazuhide Suyama; Koichi Hashimoto; Junzo Suzuki; Hitoshi Suzuki; Mitsuaki Hosoya
Journal:  Pediatr Nephrol       Date:  2007-02-03       Impact factor: 3.714

3.  Should a 4-year-old girl with steroid-resistant nephrotic syndrome, hypercholesterolaemia and hypertriglyceridaemia be treated with lipid-lowering agents?

Authors:  U Querfeld
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

Review 4.  Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.

Authors:  M Haria; D McTavish
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

5.  Monascus purpureus Went rice in nephrotic hyperlipidemia.

Authors:  O Gheith; H Sheashaa; M Sobh; M Abdelsalam; Z Shoeir
Journal:  Indian J Nephrol       Date:  2008-04

6.  Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia.

Authors:  Osama Gheith; Hussein Sheashaa; Mohamed Abdelsalam; Zaki Shoeir; Mohamed Sobh
Journal:  Clin Exp Nephrol       Date:  2008-03-26       Impact factor: 2.801

7.  Dextran-Sulfate Plasma Adsorption Lipoprotein Apheresis in Drug Resistant Primary Focal Segmental Glomerulosclerosis Patients: Results From a Prospective, Multicenter, Single-Arm Intervention Study.

Authors:  Rupesh Raina; Vinod Krishnappa; Cheryl Sanchez-Kazi; Alejandro Quiroga; Katherine E Twombley; Robert Mathias; Megan Lo; Ronith Chakraborty; Shefali Mahesh; Julia Steinke; Timothy Bunchman; Joshua Zaritsky
Journal:  Front Pediatr       Date:  2019-12-03       Impact factor: 3.418

8.  Establishment of relapse risk model and multivariate logistic regression analysis on risk factors of relapse in children with primary nephrotic syndrome.

Authors:  Qian-Qian Peng; Ping Zeng; Xiao-Hua Jiang; Feng-Jun Guan
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.